Christian Schwoppe
Muenster, NW 48149, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.
Journal: Scientific reports
Published: September 27, 2025
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.
Journal: Cancer gene therapy
Published: March 08, 2023
Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.
Journal: Journal of hematology & oncology
Published: July 08, 2022
Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease.
Journal: Cancers
Published: October 18, 2021
Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
Journal: Cancers
Published: May 19, 2021
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Journal: Cancers
Published: May 18, 2020
Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
Journal: British journal of haematology
Published: April 15, 2020
Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
Journal: PloS one
Published: June 01, 2019
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.
Journal: Translational oncology
Published: August 06, 2018
Last Updated: 09/26/2026